6.75
+1.18(+21.18%)
Currency In USD
| Previous Close | 5.57 |
| Open | 5.53 |
| Day High | 6.85 |
| Day Low | 5.39 |
| 52-Week High | 10.48 |
| 52-Week Low | 2.28 |
| Volume | 1.63M |
| Average Volume | 466,947 |
| Market Cap | 260.46M |
| PE | -4.86 |
| EPS | -1.39 |
| Moving Average 50 Days | 4.6 |
| Moving Average 200 Days | 3.81 |
| Change | 1.18 |
If you invested $1000 in Protara Therapeutics, Inc. (TARA) 10 years ago, it would be worth $11.91 as of November 19, 2025 at a share price of $6.75. Whereas If you bought $1000 worth of Protara Therapeutics, Inc. (TARA) shares 5 years ago, it would be worth $310.49 as of November 19, 2025 at a share price of $6.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
GlobeNewswire Inc.
7 hours ago
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and li
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that interim data from Cohort A of th
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
GlobeNewswire Inc.
Nov 04, 2025 9:05 PM GMT
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has been named a BioSpace 202